<DOC>
	<DOCNO>NCT03048344</DOCNO>
	<brief_summary>Part 1 conduct open-label , non-randomized , non-placebo-controlled dose escalation study use pre-specified dos . Subjects follow advanced hematological disorder available therapy , satisfy inclusion/exclusion criterion enrol . Part 2 consist initial randomize , open-label , 3-sequence , 3-period , crossover study evaluate bioavailability single dose oral ORH-2014 administer fed fast state ( MTD recommend dose identified Part 1 ) compare single dose IV Trisenox administer dose 0.15 mg/kg . Part 3 expansion phase conduct single-arm , open-label study evaluate safety tolerability ORH-2014 MTD recommend dose . Subjects disease type Part 1 enrol . All subject receive oral ORH-2014 MTD recommend dose initial period 12 week .</brief_summary>
	<brief_title>A Phase I , Three-part Study Determine Maximum Tolerated Dose/Recommended Dose , Compare Bioavailability Fed Fasted States , Evaluate Safety Tolerability ORH-2014 Subjects With Advanced Hematological Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>Female male subject ≥18 year age one following : Relapsed refractory acute myelocytic leukemia ( AML ) nucleophosmin1 ( NPM1 ) mutation available therapy . Relapsed refractory acute promyelocytic leukemia ( APL ) , available therapy . Note : Prior exposure arsenic trioxide allow ; however , subject fail arsenic trioxide within last 12 month allow . Relapsed refractory myelodysplastic syndrome ( MDS ) , International Prognostic Scoring System intermediate highrisk , available therapy Relapsed refractory chronic myelomonocytic leukemia ( CMML ) , MDS/myeloproliferative neoplasm ( MPN ) overlap syndrome , available therapy Relapsed refractory mantle cell lymphoma ( MCL ) adequate therapy . Negative pregnancy test Screening visit woman childbearing potential willingness use adequate birth control Not willing undergo , candidate , donor bone marrow transplantation . Eastern Cooperative Oncology Group performance status ≥3 ; Absolute myeloblast count ≥20,000/mm^3 ; Administration antineoplastic therapy within 5 halflives first dose ORH2014 Trisenox Presence remain toxicity due previous chemotherapy Participation clinical trial within least 2 week first ORH2014 Trisenox dose ; Clinical evidence active central nervous system leukemia ; Active uncontrolled infection Major surgery within 2 week prior trial entry ; Liver function test follow limit Screening : total bilirubin &gt; 1.5 x upper limit normal ( ULN ) unless relate Gilbert 's syndrome hemolysis ; aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 2.5 x ULN ; subject liver involvement , AST and/or ALT &gt; 5 x ULN ; Serum creatinine &gt; 1.5 x ULN and/or creatinine clearance estimate glomerular filtration rate &lt; 30 mL/min Impaired cardiac function Myocardial infarction unstable angina within 6 month prior plan start date study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>acute promyelocytic leukemia</keyword>
	<keyword>APL</keyword>
	<keyword>arsenic trioxide</keyword>
</DOC>